Core Viewpoint - Precision Optics Corporation is set to announce its third quarter fiscal year 2025 financial results on May 15, 2025, followed by a conference call to discuss these results [1][2]. Company Overview - Precision Optics Corporation, founded in 1982, specializes in advanced optical instruments for the medical and defense/aerospace industries, focusing on micro-optics, 3D imaging, and digital imaging technologies [5]. - The company provides comprehensive services from product concept to mass manufacturing, leveraging in-house design, regulatory, and fabrication capabilities [5]. - In healthcare, Precision Optics supports the development of enhanced imaging systems for minimally invasive surgeries and 3D endoscopy systems, catering to the needs of surgical robotic systems [5]. - The company also applies its micro-optics expertise to defense/aerospace applications, emphasizing high quality and optimization of size, weight, and power [5]. Conference Call Details - The conference call is scheduled for May 15, 2025, at 5:00 p.m. ET, with access available via phone or live webcast [3]. - Call-in numbers include (844) 735-3662 or (412) 317-5705, and the webcast can be accessed at https://app.webinar.net/XMqWYwq1mQa [3]. - A replay of the call will be available for seven days, with specific access numbers and a replay code provided [4].

Company to conduct 1x1 meetings on April 24, 2025GARDNER, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025, at 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time). Dr. Joe Forkey, Chief Executive Officer o ...

$3.1 million of new orders received during the current calendar year$6.6 million customer program backlog expected to be delivered over next 12 months$3.9 million of additional commitments expected to be received for calendar 2026 GARDNER, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced it has executed a Main Purchase Agreement whic ...

Company Overview - Precision Optics Corporation, Inc. is a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, founded in 1982 [3] - The company focuses on leveraging proprietary micro-optics, 3D imaging, and digital imaging technologies to provide services from new product concept through mass manufacture [3] - Precision Optics has capabilities in in-house design, prototype, regulatory, and fabrication, enabling the design and manufacture of next-generation product solutions [3] Industry Applications - In healthcare, Precision Optics supports next-generation medical device companies by providing enhanced and smaller imaging systems for minimally invasive surgery and 3D endoscopy systems [3] - The company has supplied a variety of optical products, including complex endocouplers and specialized endoscopes, to top-tier medical device companies for decades [3] - In the defense/aerospace sector, Precision Optics applies its technical proficiency in micro-optics to meet high-quality standards while optimizing size, weight, and power [3] Upcoming Events - Precision Optics will participate in a webcasted fireside chat at the Lytham Partners 2025 Industrials & Basic Materials Investor Summit on April 1, 2025, at 3:30 p.m. ET [1][2] - The webcast can be accessed through the conference home page or directly via a specific link, with a replay available afterward [2]

Core Insights - Precision Optics Corporation has appointed Buell Duncan to its Board of Directors, enhancing its commitment to innovation and growth [1][3] - Buell Duncan has extensive experience in technology and business sectors, having held senior leadership roles at IBM and currently serving as a Portfolio Advisor at Iron Gate Capital [2] - Dr. Richard Miles has retired from the Board after 20 years of service, with the company expressing gratitude for his contributions [3][4] Company Overview - Founded in 1982, Precision Optics is a vertically integrated optics company focused on advanced optical instruments for healthcare and defense/aerospace industries [5] - The company leverages proprietary micro-optics, 3D imaging, and digital imaging technologies to meet the demands of the surgical community and support surgical robotic systems [5] - Precision Optics has a history of supplying a variety of optical products to top-tier medical device companies, including complex endocouplers and specialized endoscopes [5]

Core Viewpoint - Precision Optics Corporation has successfully closed a registered direct offering of common stock, raising approximately $5.1 million in gross proceeds to support its growth initiatives and repay debt [1][2][3]. Group 1: Offering Details - The offering consisted of 1,272,500 shares at a purchase price of $4.00 per share, resulting in gross proceeds of approximately $5.1 million and expected net proceeds of approximately $5.0 million after deducting offering expenses [2]. - The company plans to use the net proceeds to repay certain indebtedness, expand its facilities to support expected growth, and for general working capital purposes [2]. Group 2: Company Background - Founded in 1982, Precision Optics is a vertically integrated optics company focused on advanced optical instruments for the healthcare and defense/aerospace industries [4]. - The company leverages proprietary micro-optics, 3D imaging, and digital imaging technologies to meet the demands of the surgical community and support the proliferation of surgical robotic systems [4]. - Precision Optics has a long history of supplying a variety of optical products to top-tier medical device companies, including complex endocouplers and specialized endoscopes [4].

Core Viewpoint - Precision Optics Corporation has announced a registered direct offering of 1,272,500 shares at a price of $4.00 per share, aiming to raise approximately $5.1 million in gross proceeds, with net proceeds expected to be around $5.0 million after expenses [1][2]. Group 1: Offering Details - The offering is led by existing stockholders and is expected to close on or about February 21, 2025, pending customary closing conditions [2]. - The offering is conducted under an effective shelf registration statement on Form S-3, previously filed with the SEC [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to repay certain debts, expand facilities to support anticipated growth, and for general working capital purposes [1]. Group 3: Company Overview - Precision Optics Corporation, founded in 1982, specializes in advanced optical instruments for the medical and defense/aerospace sectors, leveraging proprietary technologies in micro-optics and imaging [5]. - The company provides comprehensive services from product concept to mass manufacturing, catering to the increasing demands for enhanced imaging systems in minimally invasive surgeries and 3D endoscopy [5]. - Precision Optics also focuses on high-quality standards and optimization in size, weight, and power for defense/aerospace applications [5].

Financial Data and Key Metrics Changes - For Q2 2025, revenue was $4.5 million, down from $4.8 million in Q2 2024, slightly below the expected $5 million [38] - Manufacturing revenue increased by 42% from Q1 to Q2, marking the largest quarter-over-quarter production increase in many years [11][38] - Gross margins were 24% compared to 30% in the same quarter last year, impacted by lower sales volume and increased R&D spending [39] Business Line Data and Key Metrics Changes - The single-use cystoscope program and defense aerospace program have been ramping production, contributing significantly to revenue growth [11][26] - Production revenue in Q2 was up substantially over Q1, with expectations for record levels in Q3 and Q4 driven by these programs [26][31] Market Data and Key Metrics Changes - The single-use endoscope market is expected to grow at annual rates of up to 20%, with POC well-positioned to benefit from this trend [14] - The company has seen its Ross Optical components business stabilize at approximately $1 million per quarter, with expectations for recovery by the end of fiscal 2025 [32] Company Strategy and Development Direction - The launch of the Unity imaging platform is expected to enhance POC's competitive position by accelerating time to market and reducing development risks [21][24] - POC aims to double its product development pipeline size, requiring an increase in the engineering team to support anticipated growth [23] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about continued growth in the second half of fiscal 2025, driven by strong backlogs and a return to normalized engineering operations [12][33] - The company is addressing capacity limitations to meet demand from existing customers, which is seen as a positive indicator for future growth [34][81] Other Important Information - The company is in the process of expanding its cleanroom space and workforce to meet production demands, with significant increases in capacity expected by the end of March [85][87] - Cash balance as of December 31, 2024, was approximately $200,000, with an additional $350,000 available on the line of credit [43] Q&A Session Summary Question: Update on defense contracts with specification problems - Management confirmed two significant defense aerospace programs are in production, with one running steadily at $2 million to $2.5 million annually, and the other expected to reach a $3 million to $4 million run rate by the end of the fiscal year [55][59] Question: Details on the Unity platform - The Unity platform allows for baseline designs tailored to customer specifications, significantly accelerating the time to market by reducing development cycles [60][66] Question: Reasons for lower than expected revenue in Q2 - Management cited delays in product development due to the focus on launching the Unity platform and customer-related delays in regulatory approvals and financing [72][76] Question: Plans to increase capacity - The company is expanding cleanroom capacity and increasing workforce by approximately 80% to meet the substantial backlog in production [84][87]

Financial Data and Key Metrics Changes - For Q2 2025, revenue was $4.5 million, down from $4.8 million in Q2 2024, slightly below the expected $5 million [38] - Gross margins decreased to 24% from 30% year-over-year [39] - Net loss for the quarter was $910,000 compared to a net loss of $704,000 in the previous year [42] - Adjusted EBITDA was negative $555,000, worsening from a negative adjusted EBITDA of $269,000 last year [42] Business Line Data and Key Metrics Changes - Manufacturing revenue increased by 42% from Q1 to Q2, marking the largest quarter-over-quarter production increase in many years [11] - The single-use cystoscope program and defense aerospace program are driving production increases, with multimillion-dollar backlogs for both [26][27] - The Ross Optical components business has stabilized at approximately $1 million per quarter due to short-term market forces [32] Market Data and Key Metrics Changes - The single-use endoscope market is projected to grow at annual rates of up to 20% [14] - The company is positioned to benefit from the transition to CMOS-based endoscope systems, which are increasingly favored in the market [8][14] Company Strategy and Development Direction - The launch of the Unity imaging platform is expected to enhance the company's competitive position and accelerate time to market for new products [19][21] - The strategy involves leveraging existing designs to create baseline platforms that can be customized for specific customer needs, reducing development risks [18][19] - The company plans to double production capacity for key programs by expanding clean room space and increasing workforce [85][87] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about continued growth in Q3 and Q4, driven by strong backlogs and the return of normalized engineering operations [46][49] - The company anticipates achieving record production revenue levels in Q3 and Q4, with forecasts of $5 million in Q3 and $6 million in Q4 [43][49] - Management acknowledged capacity limitations as a challenge but emphasized robust plans to address these requirements [34][81] Other Important Information - The Unity platform was launched at major trade shows, receiving positive feedback and generating new development opportunities [24][25] - The company is finalizing facility plans to support growth and expand manufacturing capabilities [44] Q&A Session Summary Question: Update on defense contracts with specification problems - The company has two significant defense aerospace programs, one running steadily at $2 million to $2.5 million annually, and the other has resumed production after resolving measurement errors [55][56][59] Question: Details on the Unity platform - The Unity platform allows for accelerated development timelines by using baseline designs that can be quickly customized for customer needs, potentially reducing time to market by 6 to 12 months [60][70] Question: Reasons for lower-than-expected revenue in Q2 - The product development group faced delays due to the Unity launch and customer-related events that postponed activities, but these are expected to resolve in Q3 [72][76] Question: Plans to increase capacity - The company is expanding clean room capacity and increasing workforce by approximately 80% to meet the substantial backlog in production [84][87]

Core Viewpoint - Precision Optics Corporation reported its second quarter fiscal year 2025 results, highlighting a significant production growth driven by new applications and defense/aerospace programs, despite a decline in engineering revenue due to R&D investments [4][5]. Financial Highlights - Revenue for Q2 2025 was $4.5 million, a decrease from $4.8 million in Q2 2024 but an 8% increase from $4.2 million in the previous quarter [5][6]. - Production revenue reached $3.3 million, up 42% sequentially from $2.3 million and compared to $2.6 million in the same quarter last year [5][6]. - Engineering revenue fell to $1.2 million from $2.3 million year-over-year and $1.9 million sequentially [5][6]. - Gross margins were reported at 23.6%, down from 30.1% in the same quarter last year and 26.6% sequentially [5][6]. - The net loss for the quarter was $1.0 million, compared to a loss of $0.8 million in the same quarter last year and $1.3 million in the previous quarter [5][6]. Recent Developments - The company launched the Unity Imaging Platform in January 2025, aimed at transforming endoscopic imaging device development by reducing costs and time to market [5][6]. - A $340,000 production order was received from a global medical device company for a new single-use ophthalmic endoscope, with expectations for follow-on orders [5][6]. - Following FDA clearance for a single-use urological endoscope, the company accelerated production against a $9 million order, estimating $2.7 million in product deliveries for the fiscal year ending June 2025 [5][6]. Operational Insights - Production growth was noted as the highest since the end of fiscal 2023, with expectations for continued revenue growth in the second half of fiscal 2025 [4][5]. - The company anticipates improvements in gross margin and net income due to a large backlog of production programs and engineering projects [4][5].